These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16814560)

  • 21. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
    Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
    Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pharmacoeconomic evaluation of amlodipine usage in patients undergoing PTCA in the US using results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES).
    Thaulow E; Jorgensen B; Doyle JJ; Casciano R; Casciano J; Arikian S; Kim R; Arocho R; Kopp Z
    J Cardiovasc Manag; 2001; 12(2):31-5. PubMed ID: 11299932
    [No Abstract]   [Full Text] [Related]  

  • 23. [Analysis of the effectiveness and costs of amlodipine on the hospitalizations for cardiovascular events in patients with ischemic cardiopathy].
    Galduf Cabañas J; Cosín Aguilar J; Rodríguez-Padialc L; Zamorano Gómez JL; Fernández González I; Rejas Gutiérrrez J
    Rev Clin Esp; 2004 Aug; 204(8):398-404. PubMed ID: 15274762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease.
    Janzon M; Levin LA; Swahn E
    Eur Heart J; 2002 Jan; 23(1):31-40. PubMed ID: 11741360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve.
    Fearon WF; Shilane D; Pijls NH; Boothroyd DB; Tonino PA; Barbato E; Jüni P; De Bruyne B; Hlatky MA;
    Circulation; 2013 Sep; 128(12):1335-40. PubMed ID: 23946263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Safety and antihypertensive efficacy of the dihydropyridine calcium antagonist Amlodipine besylate--results from an observational study in 9,672 patients].
    Keck M; Sauerbrey-Wullkopf N; Regourd E; Clemens A
    MMW Fortschr Med; 2004 Dec; 146(Suppl 3-4):115-21. PubMed ID: 15662901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).
    Amin AP; Reynolds MR; Lei Y; Magnuson EA; Vilain K; Durtschi AJ; Simonton CA; Stone GW; Cohen DJ
    Am J Cardiol; 2012 Sep; 110(6):765-70. PubMed ID: 22651880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study.
    Favarato D; Hueb W; Gersh BJ; Soares PR; Cesar LA; da Luz PL; Oliveira SA; Ramires JA;
    Circulation; 2003 Sep; 108 Suppl 1():II21-3. PubMed ID: 12970202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators.
    Pitt B; Byington RP; Furberg CD; Hunninghake DB; Mancini GB; Miller ME; Riley W
    Circulation; 2000 Sep; 102(13):1503-10. PubMed ID: 11004140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME).
    Claude J; Schindler C; Kuster GM; Schwenkglenks M; Szucs T; Buser P; Osswald S; Kaiser C; Grädel C; Estlinbaum W; Rickenbacher P; Pfisterer M;
    Eur Heart J; 2004 Dec; 25(24):2195-203. PubMed ID: 15589636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
    Ferrario CM; Panjabi S; Buzinec P; Swindle JP
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):27-39. PubMed ID: 23328188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension.
    Park S; Chung N; Kwon J; Yoon JH; Kim YJ; Han DS; Kim HS
    Clin Ther; 2005 Apr; 27(4):441-50. PubMed ID: 15922817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.